Scott N. Lim

FDA investigator

Appears on 14 documents from 2019 to 2026, mostly at sites in California. Most often cites testing and release for distribution (21 CFR 211.165(a)).

14
Documents on file
2.3
Observations per 483
2019
First seen
2026
Most recent

What they cite most

From 32 observations

Activity by year

2019: 1, 2020: 3, 2021: 4, 2022: 2, 2023: 2, 2024: 1, 2026: 1

Where

California 10 · Canada 1 · Idaho 1 · Nevada 1 · South Korea 1

Is Scott N. Lim coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

14 documents, newest first
FirmOpen
483 Ascendis Pharma LLCMar 6, 2026 · Palo Alto, California
483 ASEGUA THERAPEUTICS LLCJan 22, 2024 · Foster City, California
483 Samsung Bio e p is Co ., LtdSep 15, 2023 · Yeonsu, South Korea
483 Genentech, Inc.Aug 11, 2023 · South San Francisco, California
483 Apollo Health and Beauty CareApr 15, 2022 · Toronto, Canada
483 Ark Pharmacy, PCFeb 17, 2022 · Newbury Park, California
483 Allure Labs, LLCDec 3, 2021 · Hayward, California

About this profile

What does Scott N. Lim inspect?

Scott N. Lim appears on 14 documents on file covering 14 sites, mostly in California.

What do they cite most often?

21 CFR 211.165(a) (testing and release for distribution), followed by 21 CFR 211.113 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Scott N. Lim is dated Mar 6, 2026.

FDA Investigator Scott N. Lim: 483s & Inspections · FDA Intel